In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
Others have stated their priorities directly with Federal Government. Through these interviews, AHJ gives a final opportunity to communicate to all health stakeholders, the funding needs for a range of priorities. These range from new models of care to pilots and wholesale, system improvements to building more sustainable workforces to help grow certain sectors of the health system
The CEO of Allied Health Professions Australia (AHPA), Bronwyn Morris-Donovan spoke with Australian Health Journal about the following:
- The structure and priorities for AHPA
- The setting and disciplines in Allied Health
- Allied Health representation in the Strengthening Medicare Task Force
- Importance of a data strategy and interoperability in delivery of allied health services
Lastly Bronwyn talks about the allied health priorities she hopes are included in the Federal Budget.
The first is the funding to support the delivery and implementation of the allied workforce strategy across the various settings where allied health is delivered. This includes health, disability, aged care and education settings. This should “genuinely look at issues of supply and distribution across multiple setting.”, says Bronwyn.
The second key priority is further work and investment with the Australian Digital Health Agency to build the interoperability needed for allied health to be able to upload to My Health Record. This access is an enabler to multidisciplinary team care and is a core recommendation of the Strengthening Medicare Task Force report; to enhance, build and foster multidisciplinary team care. Bronwyn states this is only possible by bringing allied health into the digital ecosystem through better digital interoperability.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Clinical entrepreneur addresses needle-phobia
Australian entrepreneur, Lauren Barber, turned her nursing background into the role of an inventor and launched a medical device into the Australian healthcare industry.
No journey is linear for an entrepreneur, but Lauren has travelled considerable distance from a nursing student to a successful entrepreneur illustration her determination and passion to help those with needle phobias. Lauren’s work with NeedleCalm is making a positive impact in the healthcare industry and improving the experiences of patients and clinicians alike.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
